Integrating GPRC5D-Targeting Bispecifics for Relapsed/Refractory MM

Data from the CEPHEUS trial support the use of D-VRd in patients with transplant-ineligible or -deferred multiple myeloma who can tolerate bortezomib.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Elotuzumab plus pomalidomide, bortezomib, and dexamethasone showed tolerability in patients with relapsed or refractory multiple myeloma.

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

Real-world data show that older adults with lenalidomide-refractory MM have poor survival outcomes after 1 to 3 lines of therapy.

Median time to sustained worsening of symptoms was 23.7 months with cilta-cel, compared with 18.9 months with SOC.